Form 8-K

8-K — Lantern Pharma Inc.

Accession: 0001493152-26-035864

Filed: 2026-08-03

Period: 2026-08-03

CIK: 0001763950

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001763950

2026-08-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 3, 2026

Lantern

Pharma Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

1920

McKinney Avenue, 7th Floor

Dallas,

Texas

75201

(Address

of Principal Executive Offices)

(Zip

Code)

(972)

277-1136

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act: Common Stock

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, $0.0001 par value

LTRN

The

Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

August 3, 2026, Lantern Pharma Inc. (“Lantern”) issued a press release announcing the establishment of Open-Medicine AI as

a separate company to commercialize and expand its multi-agent AI co-scientist platform for drug development. A copy of the press release

is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless

of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Exhibit

Description

99.1

Press Release dated August 3, 2026 announcing the establishment of Open-Medicine AI.

104

Cover

Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Lantern

Pharma Inc.,

Delaware Corporation

Dated:

August 3, 2026

By:

/s/

David R. Margrave

David

R. Margrave, Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Lantern

Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist

Platform for the Transformation of Medicine

●

The

Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional

disease areas and modalities.

●

The

creation of the new entity, signed commercial licenses, and Board approvals are consistent with the agreements entered into in connection

with Lantern’s May financing.

●

Lantern

Pharma has executed commercial licensing agreements with Open-Medicine AI granting access to Lantern’s withZeta.ai-related

models, data, algorithms, and other assets and personnel.

●

The

global AI drug discovery and development market is projected to exceed $10 billion by 2030, and Open-Medicine AI enters this market

with a differentiated multi-agentic, highly curated platform built for real-world drug development rather than a general-purpose

AI.

(BUSINESS

WIRE) DALLAS – August 3, 2026 — Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company,

today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI

and Lantern Pharma. The agreements, which have received Lantern Pharma Board approval, are consistent with the framework outlined in

Lantern’s most recent registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist

platform previously launched as withZeta.ai.

OMAI

will continue to advance the multi-agentic architecture, first proven in oncology and rare cancer research, while expanding its application

across broader disease areas. The formation of the entity and the licensing arrangements position OMAI for independent growth, while

expanding value creation opportunities and preserving strategic alignment with Lantern Pharma’s clinical programs and shareholders.

“The

creation of Open-Medicine AI and the execution of these licensing agreements mark a significant milestone,” said Panna Sharma,

President and CEO of Lantern Pharma and Founder of Open-Medicine AI. “withZeta.ai demonstrated that a true multi-agentic co-scientist

— specialized agents working in coordinated intelligence rather than a single model answering isolated questions — can dramatically

compress research timelines and reduce the cost of generating hardened, actionable scientific insights. Open-Medicine AI takes that proven

foundation and gives it the corporate structure, commercial licenses, and operational focus needed to scale across oncology and into

additional complex disease areas.”

Lantern Launches Open-Medicine AI : From Idea to Medicine at the Speed of Insight

Lantern Pharma (Nasdaq: LTRN) Aug 3, 2026

Centers of Excellence in Dallas, Texas and Bengaluru, India

the first quarter of 2026, Lantern established and staffed an AI Center of Excellence in Bengaluru, India. This center will serve as

a core operational hub accelerating the development, refinement, and scaling of the Open-Medicine platform. The Bengaluru team will bring

additional specialized talent to the existing team in Dallas (where Lantern is also headquartered). Both sites will focus on functional

enhancements in multi-agent systems, computational biology modeling, knowledge engineering, and large-scale scientific curation —

furthering Open-Medicine’s ability to deliver production-grade capabilities to researchers and institutions worldwide.

Market

Need and Competitive Landscape

The

global market for AI-enabled drug discovery and development tools is projected to exceed $10 billion by 2030, with oncology representing

the largest therapeutic segment and compound annual growth rates above 30 percent. The underlying need is structural: traditional drug

development remains slow, expensive, and poorly suited to the hundreds of rare and complex diseases that lack commercial scale under

conventional models. Knowledge remains fragmented across literature, clinical trial databases, institutional archives, and individual

expertise, while experimental iteration continues to consume months or years and hundreds of thousands to millions of dollars per cycle.

the same time, major general-purpose AI companies — including Anthropic and OpenAI — have publicly signaled or begun developing

platforms and tools aimed at scientific discovery and drug development. Their entrance validates the long-term importance of AI co-scientists

while also highlighting the differentiation required for durable impact. While general models excel at broad reasoning and language,

domain-specific multi-agentic systems grounded in curated ontologies, domain-specific computational tools, and disease-area expertise

are required to deliver the precision, auditability, and scientific rigor demanded by drug development.

OMAI

is uniquely positioned for differentiated value creation at this intersection. Built from the ground up for oncology and rare disease

research and drug-development, the platform combines specialized agent roles, recursive investigation modes, living knowledge graphs,

and production tools (including blood-brain barrier prediction, multi-omic analytics via ZetaOmics™, and generative chemistry capabilities).

Its architecture is designed not merely to retrieve information but to generate, stress-test, and harden insights in a manner that mirrors

how expert scientific teams actually work – iteratively, collaboratively and focused on actionable results.

Lantern Launches Open-Medicine AI : From Idea to Medicine at the Speed of Insight

Lantern Pharma (Nasdaq: LTRN) Aug 3, 2026

The

May 2026 financing of Lantern Pharma’s registered direct was led by Empery Asset Management, LP and also included an existing institutional

healthcare investor and Lantern Board members. Mr. Ryan Lane, CIO and founder of Empery Asset Management stated,

“At

Empery, we continue to be impressed by the relevance and usefulness of the insights and results generated by withZeta.AI’s co-scientist

platform. Among the various enterprise level agentic AI toolings we use, withZeta.AI continues to be our preferred platform for AI-assisted

biopharma due diligence and research.”

Platform

Foundation and Expansion Path

OMAI

inherits the full multi-agentic system originally commercialized as withZeta.ai, including:

●

Coordinated

specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers & translational science,

clinical oncology, and general research.

●

Three

research modes (Explorer, Investigator, Reporter) that support rapid exploration through deep multi-source investigation to structured

reporting.

●

Proprietary

rare-cancer knowledge bases and ontologies covering hundreds of disease entities, biomarkers, clinical trials, and literature.

●

Expanding

computational layers, including ZetaOmics™ for multi-omic analysis and continued development of parallel swarm intelligence

capabilities.

While

rare cancers remain a core component, OMAI’s roadmap includes systematic expansion into additional high-need disease areas –

especially in collaboration with leading academic and commercial leaders – that experience the same challenges of fragmented

knowledge, high failure costs, limited traditional investment and urgency of patient and disease management needs.

“Open-Medicine

AI is built to change how medicines are discovered and developed globally, and as a separate company, to pursue dedicated funding and

a valuation path distinct from Lantern’s clinical activity and operations.” – Panna Sharma, CEO & President

of Lantern Pharma

About

Lantern Pharma Inc.

Lantern

Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging artificial intelligence and machine learning to

transform cancer therapy development. The Company’s pipeline includes LP-184, LP-284, and LP-300. Lantern established an AI Center

of Excellence in Bengaluru, India, in the first quarter of 2026 and has commercialized its multi-agentic AI capabilities through the

platform now operating as Open-Medicine AI (OMAI).

Lantern Launches Open-Medicine AI : From Idea to Medicine at the Speed of Insight

Lantern Pharma (Nasdaq: LTRN) Aug 3, 2026

About

Open-Medicine AI (OMAI)

Open-Medicine

AI builds multi-agentic systems that do the work of a research team — generating novel insights, interrogating literature and data,

and pressure-testing conclusions until they hold, all with transparent, auditable reasoning. The platform was built inside active drug

development at Lantern Pharma, where its output and insights had to survive contact with real programs, real regulators, and real patients.

Most discovery AI has never been held to that standard. Open-Medicine AI is planned to operate beyond rare cancers, across oncology and

into other diseases where the science is hard and the answers are overdue.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating

to: future events or our future financial performance; the establishment of our Open-Medicine AI platform (formerly referred to as withZeta.ai)

as a separate business entity and the anticipated benefits of such separation; the formation, re-branding and planned commercialization

of our Open-Medicine AI platform; the planned development, design, capabilities, and commercial potential of the Open-Medicine AI platform,

including the role of the Bengaluru AI Center of Excellence; our broader product, clinical, and platform roadmap, including future directions

for Open-Medicine AI and the planned implementation of new features; the potential advantages of our Open-Medicine AI platform in identifying

drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models; the planned

commercialization of Open-Medicine AI, and the expected market opportunity for AI co-scientist platforms; our intention to leverage artificial

intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development;

and estimates regarding potential markets and potential market sizes.

Any

statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,”

“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”

“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”

“target,” “model,” “objective,” “aim,” “upcoming,” “should,”

“will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking

statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by

the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required

to advance and support our existing and planned development programs and operations, (ii) the risk that our Open-Medicine AI commercialization

efforts may not generate the anticipated revenue or achieve the expected market adoption, (iii) the risk that implementation of our product

development plans and new features for Open-Medicine AI may not be successful or may take longer than anticipated for development, completion,

and release, (iv) the risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise

been incorporated into a commercial product, and (v) technical, scientific, regulatory, financial, competitive, and operational risks

and those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025,

filed with the Securities and Exchange Commission on March 30, 2026.

You

may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com

or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking

statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements

will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this

press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update

any forward-looking statements to conform the statement to actual results or changes in our expectations.

Investor

Relations Contact

Lantern

Pharma Inc.

E-mail:

ir@lanternpharma.com

Website:

ir.lanternpharma.com

Phone:

+1-972-277-1136

Lantern Launches Open-Medicine AI : From Idea to Medicine at the Speed of Insight

Lantern Pharma (Nasdaq: LTRN) Aug 3, 2026

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (93113 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 03, 2026

Entity File Number

001-39318

Entity Registrant Name

Lantern

Pharma Inc.

Entity Central Index Key

0001763950

Entity Tax Identification Number

46-3973463

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1920

McKinney Avenue

Entity Address, Address Line Two

7th Floor

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

(972)

Local Phone Number

277-1136

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value

Trading Symbol

LTRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration